Browsing by Author "Yan, Han"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Case fatality risk of the first pandemic wave of novel coronavirus disease 2019 (COVID-19) in China
    (Oxford University Press, 2020-05-15) Deng, Xiaowei; Yang, Juan; Wang, Wei; Wang, Xiling; Zhou, Jiaxin; Chen, Zhiyuan; Li, Jing; Chen, Yinzi; Yan, Han; Zhang, Juanjuan; Zhang, Yongli; Wang, Yan; Qiu, Qi; Gong, Hui; Wei, Xianglin; Wang, Lili; Sun, Kaiyuan; Wu, Peng; Ajelli, Marco; Cowling, Benjamin J.; Viboud, Cecile; Yu, Hongjie; Epidemiology, School of Public Health
    Objective To assess the case fatality risk (CFR) of COVID-19 in mainland China, stratified by region and clinical category, and estimate key time-to-event intervals. Methods We collected individual information and aggregated data on COVID-19 cases from publicly available official sources from December 29, 2019 to April 17, 2020. We accounted for right-censoring to estimate the CFR and explored the risk factors for mortality. We fitted Weibull, gamma, and lognormal distributions to time-to-event data using maximum-likelihood estimation. Results We analyzed 82,719 laboratory-confirmed cases reported in mainland China, including 4,632 deaths, and 77,029 discharges. The estimated CFR was 5.65% (95%CI: 5.50%-5.81%) nationally, with highest estimate in Wuhan (7.71%), and lowest in provinces outside Hubei (0.86%). The fatality risk among critical patients was 3.6 times that of all patients, and 0.8-10.3 fold higher than that of mild-to-severe patients. Older age (OR 1.14 per year; 95%CI: 1.11-1.16), and being male (OR 1.83; 95%CI: 1.10-3.04) were risk factors for mortality. The time from symptom onset to first healthcare consultation, time from symptom onset to laboratory confirmation, and time from symptom onset to hospitalization were consistently longer for deceased patients than for those who recovered. Conclusions Our CFR estimates based on laboratory-confirmed cases ascertained in mainland China suggest that COVID-19 is more severe than the 2009 H1N1 influenza pandemic in hospitalized patients, particularly in Wuhan. Our study provides a comprehensive picture of the severity of the first wave of the pandemic in China. Our estimates can help inform models and the global response to COVID-19.
  • Thumbnail Image
    Item
    Connectomic profiling and Vagus nerve stimulation Outcomes Study (CONNECTiVOS): a prospective observational protocol to identify biomarkers of seizure response in children and youth
    (BMJ, 2022-04-08) Siegel, Lauren; Yan, Han; Warsi, Nebras; Wong, Simeon; Suresh, Hrishikesh; Weil, Alexander G.; Ragheb, John; Wang, Shelly; Rozzelle, Curtis; Albert, Gregory W.; Raskin, Jeffrey; Abel, Taylor; Hauptman, Jason; Schrader, Dewi V.; Bollo, Robert; Smyth, Matthew D.; Lew, Sean M.; Lopresti, Melissa; Kizek, Dominic J.; Weiner, Howard L.; Fallah, Aria; Widjaja, Elysa; Ibrahim, George M.; Neurological Surgery, School of Medicine
    Introduction: Vagus nerve stimulation (VNS) is a neuromodulation therapy that can reduce the seizure burden of children with medically intractable epilepsy. Despite the widespread use of VNS to treat epilepsy, there are currently no means to preoperatively identify patients who will benefit from treatment. The objective of the present study is to determine clinical and neural network-based correlates of treatment outcome to better identify candidates for VNS therapy. Methods and analysis: In this multi-institutional North American study, children undergoing VNS and their caregivers will be prospectively recruited. All patients will have documentation of clinical history, physical and neurological examination and video electroencephalography as part of the standard clinical workup for VNS. Neuroimaging data including resting-state functional MRI, diffusion-tensor imaging and magnetoencephalography will be collected before surgery. MR-based measures will also be repeated 12 months after implantation. Outcomes of VNS, including seizure control and health-related quality of life of both patient and primary caregiver, will be prospectively measured up to 2 years postoperatively. All data will be collected electronically using Research Electronic Data Capture. Ethics and dissemination: This study was approved by the Hospital for Sick Children Research Ethics Board (REB number 1000061744). All participants, or substitute decision-makers, will provide informed consent prior to be enrolled in the study. Institutional Research Ethics Board approval will be obtained from each additional participating site prior to inclusion. This study is funded through a Canadian Institutes of Health Research grant (PJT-159561) and an investigator-initiated funding grant from LivaNova USA (Houston, TX; FF01803B IIR).